MY THOUGHTS: While the pharma industry is in a crisis of trust and reputation the Digital Pharma conference carries on like they haven’t a care in the world with presentations from vendors who want to sell DTC marketers on their products. Houston, we have a problem.
Continue reading
MY THOUGHT: Digital pharma East is about to begin but has anything changed? If you look at new pharma websites, and metrics like bounce rates and tie on-site, over time, nothing has changed. We must acknowledge that healthcare digital marketing is unique not only because it’s healthcare but because each health issue has different metrics primarily driven by patients.
Continue reading
SUMMARY: Make no mistake about it; change is coming to healthcare. What that change will entail and actually look like is anybody’s guess but pharma companies cannot continue to ignore the prevailing wind of change.
Continue reading
SUMMARY: PulsePoint™ connects the dots of healthcare marketing and delivers health messaging where audiences are in their healthcare journey. The platform accesses contextualized health content and related, engaged audiences to deliver relevant marketing messages through partner platforms like Facebook, Instagram, Pinterest, and Twitter, as well as native, video, content discovery, search, display, and connected TV channels. But there are still issues with programmatic.
Continue reading
SUMMARY: The opioid crisis is a picture of a healthcare system that failed us all. Drug companies, distributors and retailers put sales above people and we are all paying the price.
Continue reading
KEY TAKEAWAY: Drug pricing in pharma DTC ads is not going to affect the prices of drugs. The list price doesn’t mean a damn thing to patients who have any health insurance. However, a lawsuit against pricing in ads is going to a PR nightmare for pharma companies.
Continue reading
IN SUMMARY: A study, in the journal JAMA Network Open, found a substantial industry-wide rise in insurer and out-of-pocket costs for top-selling, brand-name prescription drugs, highlighting one of the foremost problems in health care today: unimpeded price increases in the pharmaceutical market. Pharma companies are daring the government to intervene in the drug pricing debate.
Continue reading
